Skip to main content
. Author manuscript; available in PMC: 2024 Jan 27.
Published in final edited form as: J Med Chem. 2023 Apr 7;66(8):5657–5668. doi: 10.1021/acs.jmedchem.2c02089

Figure 3. JSD26 is a selective SCoR2 inhibitor.

Figure 3.

(A) IC50 value of JSD26 against the SNO-CoA-metabolizing activity of SCoR2 (n=3). (B) IC50 value of JSD26 against the methylglyoxylate-metabolizing activity of AKR1B1 (n=3). (C) SNO-CoA-metabolic activity in kidneys from JSD26-treated mice (i.p. at indicated dose, 18h) vs vehicle-treated WT and SCoR−/− mice (n≥3). (D) Methylglyoxylate-metabolizing (AKR1B1) activity in kidneys from JSD26-treated mice (i.p. 120 mg/kg, 18h) (n≥5). (E) SNO-CoA-metabolizing activity in liver, lung, heart, brain and spleen from JSD26-treated mice (i.p. 120 mg/kg, 18h) (n≥3). All results are presented as mean ± SD. Two-tailed Student’s t-test was used to detect significance. *, p<0.05; NS, no significant.